Vy Phan-Lai 1 , Yushe Dang 1 , Ekram Gad 1 , Jennifer Childs 1 , Mary L Disis 2 . Show Affiliations »
Abstract
PURPOSE: Infusion of HER2-specific T cells, derived from vaccine-primed patients and expanded with IL2/IL12, has induced tumor regression in a minority of patients with metastatic treatment-refractory HER2(+) breast cancer. We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu murine mammary tumor model, we cultured T cells derived from mice immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused naïve splenocytes (P < 0.05). T cells cultured with IL2/IL21 could uniquely mediate complete regression of spontaneous mammary tumors. IL2/IL21 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of TNFα and IL17 (P < 0.05). Moreover, tumor-infiltrating CD8(+) cells were significantly increased after the infusion of IL2/IL21 cultured T cells as compared with tumors treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of IL2/IL21 cultured cells was mediated by CD8 T cells. Depletion of TNFα or IL17, but not IFNγ, abrogated the tumor growth inhibition induced by the IL2/IL21 T cells and markedly decreased the influx of CD8 into tumors. Finally, IL2/IL21-cultured human antigen specific T cells also displayed a similar polyfunctional Th1/Th17 phenotype. CONCLUSIONS: Expansion of HER2 vaccine-primed T cells with IL2/IL21 may have the potential to effectively mediate tumor regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16. ©2015 AACR. ©2015 American Association for Cancer Research.
PURPOSE: Infusion of HER2 -specific T cells, derived from vaccine-primed patients and expanded with IL2 /IL12, has induced tumor regression in a minority of patients with metastatic treatment-refractory HER2 (+) breast cancer . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu murine mammary tumor model, we cultured T cells derived from mice immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused naïve splenocytes (P < 0.05). T cells cultured with IL2 /IL21 could uniquely mediate complete regression of spontaneous mammary tumors . IL2 /IL21 cultured neu -specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of TNFα and IL17 (P < 0.05). Moreover, tumor -infiltrating CD8 (+) cells were significantly increased after the infusion of IL2 /IL21 cultured T cells as compared with tumors treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of IL2 /IL21 cultured cells was mediated by CD8 T cells. Depletion of TNFα or IL17 , but not IFNγ, abrogated the tumor growth inhibition induced by the IL2 /IL21 T cells and markedly decreased the influx of CD8 into tumors . Finally, IL2 /IL21 -cultured human antigen specific T cells also displayed a similar polyfunctional Th1 /Th17 phenotype. CONCLUSIONS: Expansion of HER2 vaccine-primed T cells with IL2 /IL21 may have the potential to effectively mediate tumor regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16. ©2015 AACR. ©2015 American Association for Cancer Research.
Entities: CellLine
Chemical
Disease
Gene
Species
Mesh: See more »
Substances: See more »
Year: 2015
PMID: 26660518 PMCID: PMC4854769 DOI: 10.1158/1078-0432.CCR-15-2273
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531